This ‘Common Warts-Market Insights, Epidemiology, and Market Forecast-2032' report deliver an in-depth understanding of the Common Warts, historical and forecasted epidemiology as well as the Common Warts market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
The Common Warts market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM plus China Common Warts market size from 2019 to 2032. The Report also covers current Common Warts treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Common warts, also known as verruca vulgaris, are caused by nonmalignant strains of human papillomavirus (HPV). They are typically benign lesions that rarely have malignant transformation. On the skin, they appear as rough, painless papules that can be grey or flesh-colored and are found on different body areas. Other subtypes of HPV that are associated with cervical cancer are not the same strains that cause verruca vulgaris.
Most warts are harmless and will go away on their own within a few weeks or months. But they can be bothersome and unattractive, and some people feel ashamed. There are several different treatments that can make warts go away more quickly - but they do not always work. There are over 100 subtypes of the HPV virus, but only a few types can cause skin warts at selective anatomical sites. However, with skin contact, the HPV can be transferred to any body part. Common warts are associated with HPV types 2, 4 (most common), followed by types 1, 3, 27, 29, and 57.
Characteristics of the common wart include: round or oval-shaped; raised from the skin; firm, rough surface; variable size; and with a diameter within the range of 1 millimeter (mm) to 1 centimeter (cm).
The diagnosis of verruca vulgaris can be made after a small piece of the growth is removed in a procedure called a biopsy or after the entire growth is removed in a procedure called an excision. The tissue is then sent to a pathologist who examines it under the microscope.
Common Warts Treatment
Treating warts is a therapeutic challenge for physicians. Although many different approaches exist, including observation and treatments combined for greater effectiveness, no single therapy has been proven effective at achieving complete remission in every patient. Verruca Vulgaris, the most common, manifests as hyperkeratotic papules, often on the hand.
The goals of treatment are to destroy the wart, stimulate an immune system response to fight the virus, or both. Treatment may take weeks or months. Even with treatment, warts tend to recur or spread. Doctors generally start with the least painful methods, especially when treating young children.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Common Warts, and gender-specific diagnosed prevalent cases of Common Warts in the 7MM plus China covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2019 to 2032.
The epidemiology segment also provides the Common Warts epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
The drug chapter segment of the Common Warts report encloses the detailed analysis of Common Warts mid-phase, and late-stage pipeline drugs. It also helps to understand the Common Warts clinical trial details, expressive pharmacological action, agreements and collaborations, and patent details of each included drug and the latest news and press releases.
Candin: Nielsen Bioscience
Nielsen Bioscience's Candin is one of the most promising molecule being developed to treat common warts. It is an intralesional administered therapy. The results of Phase II clinical trial involving common and non-common warts among adults were highly encouraging and are now advancing clinical research into the use of the antigen in common and non-common warts.
VP-102: Verrica Pharmaceutical
VP-102 is being developed by Verrica Pharmaceutical as a controlled, shelf-stable drug-device combination product with a topical solution that contains cantharidin (0.7% w/v). In the Phase II trial, VP-102 Cantharidin showed efficacy in complete clearance of common warts from baseline to Day 84, as well as at follow-up visits. Due to the pandemic situation occurred in past years, in 2020, the clinical studies for common warts and plantar warts was putted on hold for the undefined time period.
List to be continued in the report…
Different treatment methods are available for common warts at present, but none is universally fully effective. The majority of viral warts will spontaneously resolve on their own within 2 years. However, recurrence is very common.
Salicylic acid is used as a stronger peeling medicine to treat common warts. Prescription-strength wart medications with salicylic acid work by removing layers of a wart a little bit at a time. Studies show that salicylic acid is more effective when combined with freezing.
Other treatment approach can be followed is Imiquimod, (brand name Aldara). It is popular to treat genital and anal warts, but off-label, it is also widely used to treat common warts. Imiquimod cream does not cure warts, and new warts may appear during treatment. Another topical treatment to consider is silver nitrate, a chemical cautery performed by a stick pencil applicator associated with potassium nitrate in various concentrations. This treatment is mainly used in the UK where it is sold OTC. In the US, the FDA requires a prescription for 95% silver nitrate. Another topical agent is glutaraldehyde, available as a 10% solution in aqueous ethanol or in a gel formulation. Treatment with aminolevulinic acid (Levulan Kerastick) followed by phototoxicity is the mainstay of photodynamic therapy. Formaldehyde, another antiviral agent, can be applied once daily in a 0.7% gel or at a concentration of 3-10% in solution to treat common warts. Retinoids are vitamin A derivatives (retinol) with cellular and biologic actions that include regulation of epidermal proliferation and differentiation. Both topical and oral retinoids can be employed to treat warts via inhibition of HPV replication.
According to the publisher, the Common Warts treatment paradigm in the 7MM plus China is expected to change during the forecasted period 2022-2032.
This section provides the total Common Warts market size and; market size by therapies in the United States.
The total Common Warts market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
The total Common Warts market size and market size by therapies in Japan are provided.
The total Common Warts market size and market size by therapies in China are provided.
This section focuses on the rate of uptake of the potential drugs recently launched in the Common Warts market or expected to get launched in the market during the study period 2019-2032. The analysis covers Common Warts market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.
The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Common Warts emerging therapies.
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
The publisher performs competitive and market Intelligence analysis of the Common Warts market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
The Common Warts market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM plus China Common Warts market size from 2019 to 2032. The Report also covers current Common Warts treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
- China
Common Warts Disease Understanding and Treatment Algorithm
Common Warts Overview
Common warts, also known as verruca vulgaris, are caused by nonmalignant strains of human papillomavirus (HPV). They are typically benign lesions that rarely have malignant transformation. On the skin, they appear as rough, painless papules that can be grey or flesh-colored and are found on different body areas. Other subtypes of HPV that are associated with cervical cancer are not the same strains that cause verruca vulgaris.
Most warts are harmless and will go away on their own within a few weeks or months. But they can be bothersome and unattractive, and some people feel ashamed. There are several different treatments that can make warts go away more quickly - but they do not always work. There are over 100 subtypes of the HPV virus, but only a few types can cause skin warts at selective anatomical sites. However, with skin contact, the HPV can be transferred to any body part. Common warts are associated with HPV types 2, 4 (most common), followed by types 1, 3, 27, 29, and 57.
Characteristics of the common wart include: round or oval-shaped; raised from the skin; firm, rough surface; variable size; and with a diameter within the range of 1 millimeter (mm) to 1 centimeter (cm).
Common Warts Diagnosis
The diagnosis of verruca vulgaris can be made after a small piece of the growth is removed in a procedure called a biopsy or after the entire growth is removed in a procedure called an excision. The tissue is then sent to a pathologist who examines it under the microscope.
Common Warts Treatment
Treating warts is a therapeutic challenge for physicians. Although many different approaches exist, including observation and treatments combined for greater effectiveness, no single therapy has been proven effective at achieving complete remission in every patient. Verruca Vulgaris, the most common, manifests as hyperkeratotic papules, often on the hand.
The goals of treatment are to destroy the wart, stimulate an immune system response to fight the virus, or both. Treatment may take weeks or months. Even with treatment, warts tend to recur or spread. Doctors generally start with the least painful methods, especially when treating young children.
Common Warts Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total diagnosed prevalent cases of Common Warts, and gender-specific diagnosed prevalent cases of Common Warts in the 7MM plus China covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China from 2019 to 2032.
Key Findings
- As per the assessment of the publisher, total diagnosed prevalent cases of Common Warts in the 7MM + China were found to be approximately 21,826,945 in 2021, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 0.2% during study period.
- Among 7MM + China, the United States had approximately 2,805,077 diagnosed prevalent cases of Common Warts in 2021, which was equivalent to 13% of total diagnosed prevalent cases in 7MM + China.
- In 2021, the EU-5 accounted for approximately 10,761,864 diagnosed prevalent cases of Common Warts, which are expected to increase by 2032 at a CAGR of 0.2%.
- As per The 's assessment, among 7MM + China, China recorded highest diagnosed prevalent cases of Common Warts with approximately 6,894,784 cases in 2021, which was equivalent to 32% of total diagnosed prevalent cases in 7MM + China.
- In 2021, Japan had 1,365,220 diagnosed prevalent cases of Common Warts ranking lowest among the 7MM + China. These cases are expected to decrease by 2032 at a CAGR of -0.4% during the forecasted period (2022-2032).
- Based on the literature review, it can be concluded that Common Warts can affects male and female equally. A very slight difference was observed between the both genders in the 7MM + China.
Common Warts Epidemiology
The epidemiology segment also provides the Common Warts epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, and China.
Common Warts Drug Chapters
The drug chapter segment of the Common Warts report encloses the detailed analysis of Common Warts mid-phase, and late-stage pipeline drugs. It also helps to understand the Common Warts clinical trial details, expressive pharmacological action, agreements and collaborations, and patent details of each included drug and the latest news and press releases.
Common Warts Emerging Drugs
Candin: Nielsen Bioscience
Nielsen Bioscience's Candin is one of the most promising molecule being developed to treat common warts. It is an intralesional administered therapy. The results of Phase II clinical trial involving common and non-common warts among adults were highly encouraging and are now advancing clinical research into the use of the antigen in common and non-common warts.
VP-102: Verrica Pharmaceutical
VP-102 is being developed by Verrica Pharmaceutical as a controlled, shelf-stable drug-device combination product with a topical solution that contains cantharidin (0.7% w/v). In the Phase II trial, VP-102 Cantharidin showed efficacy in complete clearance of common warts from baseline to Day 84, as well as at follow-up visits. Due to the pandemic situation occurred in past years, in 2020, the clinical studies for common warts and plantar warts was putted on hold for the undefined time period.
List to be continued in the report…
Common Warts Market Outlook
Different treatment methods are available for common warts at present, but none is universally fully effective. The majority of viral warts will spontaneously resolve on their own within 2 years. However, recurrence is very common.
Salicylic acid is used as a stronger peeling medicine to treat common warts. Prescription-strength wart medications with salicylic acid work by removing layers of a wart a little bit at a time. Studies show that salicylic acid is more effective when combined with freezing.
Other treatment approach can be followed is Imiquimod, (brand name Aldara). It is popular to treat genital and anal warts, but off-label, it is also widely used to treat common warts. Imiquimod cream does not cure warts, and new warts may appear during treatment. Another topical treatment to consider is silver nitrate, a chemical cautery performed by a stick pencil applicator associated with potassium nitrate in various concentrations. This treatment is mainly used in the UK where it is sold OTC. In the US, the FDA requires a prescription for 95% silver nitrate. Another topical agent is glutaraldehyde, available as a 10% solution in aqueous ethanol or in a gel formulation. Treatment with aminolevulinic acid (Levulan Kerastick) followed by phototoxicity is the mainstay of photodynamic therapy. Formaldehyde, another antiviral agent, can be applied once daily in a 0.7% gel or at a concentration of 3-10% in solution to treat common warts. Retinoids are vitamin A derivatives (retinol) with cellular and biologic actions that include regulation of epidermal proliferation and differentiation. Both topical and oral retinoids can be employed to treat warts via inhibition of HPV replication.
According to the publisher, the Common Warts treatment paradigm in the 7MM plus China is expected to change during the forecasted period 2022-2032.
Key Findings
- The market size of Common Warts in the seven major markets plus China is expected to increase at a decent Compound Annual Growth Rate (CAGR) for the study period (2019-2032) from USD 782 million in 2021 to significant market size by 2032.
- The expected launch of potential therapies may increase market size in the coming years, assisted by an increase in the diagnosed prevalent population of Common Warts.
- Upcoming therapies such as Candin, VP-102, FIT039, and some others have the potential to create a significant positive shift in the Common Warts market size.
- The United States accounts for the largest market size of Common Warts, in comparison to EU-5 (Germany, France, Italy, Spain, and the United Kingdom,), Japan, and China.
- Among the EU-5 countries, Germany had the highest market size of Common Warts throughout the study period (2019-2032).
The United States Market Outlook
This section provides the total Common Warts market size and; market size by therapies in the United States.
EU-5 Market Outlook
The total Common Warts market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Common Warts market size and market size by therapies in Japan are provided.
China Market Outlook
The total Common Warts market size and market size by therapies in China are provided.
Common Warts Drugs Uptake
This section focuses on the rate of uptake of the potential drugs recently launched in the Common Warts market or expected to get launched in the market during the study period 2019-2032. The analysis covers Common Warts market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Common Warts Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stages. It also analyzes key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, merger, licensing, and patent details for Common Warts emerging therapies.
Reimbursement Scenario in Common Warts
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
The publisher performs competitive and market Intelligence analysis of the Common Warts market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Common Warts, explaining its etiology, signs and symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the Common Warts epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for Common Warts is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the Common Warts market; historical and forecasted is included in the report, covering the 7MM plus China drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM plus China Common Warts market.
Report Highlights
- The robust pipeline with novel MOA and oral ROA and increasing prevalence will positively drive the Common Warts market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Common Warts R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Common Warts. The launch of emerging therapies will significantly impact the Common Warts market.
- Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Common Warts Report Insights
- Patient Population
- Therapeutic Approaches
- Common Warts Pipeline Analysis
- Common Warts Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Common Warts Report Key Strengths
- 11-Years Forecast
- 7MM plus China Coverage
- Common Warts Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Common Warts Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
- SWOT analysis
Key Questions
Market Insights:
- What was the Common Warts market share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Common Warts total market size as well as market size by therapies across the 7MM plus China during the forecast period (2022-2032)?
- What are the key findings pertaining to the market across the 7MM plus China and which country will have the largest Common Warts market size during the forecast period (2022-2032)?
- At what CAGR, the Common Warts market is expected to grow at the 7MM plus China level during the forecast period (2022-2032)?
- What would be the Common Warts market outlook across the 7MM plus China during the forecast period (2022-2032)?
- What would be the Common Warts market growth till 2032 and what will be the resultant market size in the year 2032?
- How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and unmet needs of Common Warts?
- What is the historical Common Warts patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), Japan, and China?
- What would be the forecasted patient pool of Common Warts at the 7MM plus China level?
- What will be the growth opportunities across the 7MM plus China with respect to the patient population pertaining to Common Warts?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Common Warts during the forecast period (2022-2032)?
- At what CAGR the population is expected to grow across the 7MM plus China during the forecast period (2022-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the treatment of Common Warts?
- What are the current treatment guidelines for the treatment of Common Warts in the US and Europe?
- How many companies are developing therapies for the treatment of Common Warts?
- How many emerging therapies are in the mid-stage and late stages of development for the treatment of Common Warts?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Common Warts therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Common Warts and their status?
- What are the key designations that have been granted for the emerging therapies for Common Warts?
- What are the 7MM plus China historical and forecasted market of Common Warts?
Reasons to Buy
- The report will help in developing business strategies by understanding trends shaping and driving Common Warts.
- To understand the future market competition in the Common Warts market and an Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for Common Warts in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), Japan, and China.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the Common Warts market.
- To understand the future market competition in the Common Warts market.
Table of Contents
1. Key Insights2. Report Introduction4. Executive Summary of Common Warts7. Patient Journey 18. Patient Journey 214. KOL Views15. Market Driver16. Market Barrier17. Unmet Needs18. SWOT Analysis20. Publisher Capabilities21. Disclaimer22. About the Publisher
3. Common Warts Market Overview at a Glance
5. Disease Background and Overview
6. Epidemiology and Patient Population
9. Current Marketed Therapies: Generics
10. Other Topical Agents
11. Emerging Therapies
12. Common Warts: Market Analysis
13. Market Outlook
19. Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Nielsen BioSciences
- Veloce BioPharma
- Verrica Pharmaceutical
- Aclaris Therapeutics, Inc.
- KinoPharma, Inc.
